Table 1 Clinicopathologic characteristics of the fistula/perforation (+) and (-) groups
Characteristics | All (n = 219) | F/P ( +)a (n = 36) | F/P (-) (n = 183) | P value |
|---|---|---|---|---|
Age, years | 51.0 ± 12.6 | 47.8 ± 12.0 | 51.6 ± 12.6 | 0.119 |
DM | 16 (7.3) | 2 (5.6) | 14 (7.7) | > 0.999 |
HTN | 36 (16.4) | 3 (8.3) | 33 (18.0) | 0.151 |
Diagnosis, year | 0.258 | |||
2007–2013 | 66 (30.1) | 8 (22.2) | 58 (31.7) | |
2014–2020 | 153 (69.9) | 28 (77.8) | 125 (68.3) | |
Histology | 0.899 | |||
SCC | 144 (65.8) | 24 (66.7) | 120 (65.6) | |
Non-SCC | 75 (34.2) | 12 (33.3) | 63 (34.4) | |
FIGO stage | 0.831 | |||
I | 61 (27.9) | 11 (30.6) | 50 (27.3) | |
II | 46 (21.0) | 7 (19.4) | 39 (21.3) | |
III | 89 (40.6) | 14 (38.9) | 75 (41.0) | |
IV | 23 (10.5) | 4 (11.1) | 19 (10.4) | |
Primary treatment | 0.312 | |||
OP | 14 (6.4) | 3 (8.3) | 11 (6.0) | |
OP + RT | 95 (43.4) | 12 (33.3) | 83 (45.4) | |
RT | 85 (38.8) | 19 (52.8) | 66 (36.1) | |
CTx | 1 (0.5) | 0 (0.0) | 1 (0.5) | |
Others | 24 (11.0) | 2 (5.6) | 22 (12.0) | |
RT modality | 0.330 | |||
EBRT alone | 23 (10.5) | 2 (5.6) | 21 (11.5) | |
EBRT + ICR | 3 (1.4) | 0 (0.0) | 3 (1.6) | |
CCRT | 118 (53.9) | 24 (66.7) | 94 (51.4) | |
CCRT + ICR | 75 (34.2) | 10 (27.8) | 65 (35.5) | |
IMRT | 85 (38.8) | 17 (47.2) | 68 (37.2) | 0.257 |
RT dose | ||||
EBRT, Gy | 54.3 ± 13.7 | 50.9 ± 8.8 | 51.1 ± 6.3 | 0.763 |
ICR, Gy | 23.4 ± 12.1 | 26.9 ± 20.9 | 23.0 ± 10.5 | 0.582 |
RT | 0.960 | |||
Primary | 188 (85.8) | 31 (86.1) | 157 (85.8) | |
After 1st recur | 31 (14.2) | 5 (13.9) | 26 (14.2) | |
Total no of recur | 0.470 | |||
1 | 93 (42.5) | 15 (41.7) | 78 (42.6) | |
2 | 75 (34.2) | 10 (27.8) | 65 (35.5) | |
≥ 3 | 51 (23.3) | 11 (30.6) | 40 (21.9) | |
Bevacizumab administration | 0.015 | |||
Yes | 144 (65.8) | 30 (83.3) | 114 (62.3) | |
No | 75 (34.2) | 6 (16.7) | 69 (37.7) |